Participated · Equity · Mar 2025

Decibel Bio is a Berkeley, CA-based company that provides an epigenetic reprogramming platform for crops. Led by CEO and founder Travis Bayer, the company develops treatments that boost genes protecting plants' photosynthetic machinery from extreme heat, helping them remain productive under stress. The same approach is described as working for drought, excess rainfall, and for yield enhancement. Decibel aims to advance its proprietary platform for both reading and writing the plant epigenome to create crop varieties with higher yield, efficiency, and resilience. The company raised $12M in funding from Breakthrough Energy Ventures, Future Ventures, Bayer and Syngenta. It intends to use the funds to expand partnerships across the platform and fast track product development.

Participated · Seed · Jan 2024

Acorai, founded in 2019, builds a handheld Heart Monitor that uses seismic, acoustic, visual and ECG sensors plus proprietary machine learning to estimate intracardiac pressures non-invasively. The device presents direct pressure estimates (not risk indices) that clinicians can incorporate into patient assessments. In pilot work in Sweden the company reported correlation above 0.8 versus right heart catheterization and high‑80s accuracy for specific pressure cutoffs; an initial pilot covered over 300 patients and 1,000+ measurements. Acorai is now running a larger global study of 1,500 patients across 14 hospitals in six countries to support validation. The company received FDA Breakthrough Device Designation for non-invasive estimation of pulmonary artery pressures and is planning to seek U.S. clearance and commercialize primarily in the U.S. in H2 2025 pending regulatory approval. The recently closed seed funding will mainly be used to finance these clinical studies and regulatory work. Acorai is building a non-invasive intracardiac pressure monitoring device intended to improve heart failure management. The company demonstrated promising results in a Swedish 350-patient pilot study and is now enrolling a global clinical validation study of 1,200 patients across 11 sites in Sweden, Denmark, Belgium, Great Britain, the US, and Canada. This global study is planned to end in 2024 and to support an FDA submission and clearance by 2025. Acorai received FDA Breakthrough Device Designation in August 2023 and was selected for the pilot FDA Total Product Life Cycle (TPLC) advisory program (TAP), enabling expedited interactions with regulators. Led by CEO Filip Peters and based in Helsingborg, Sweden, the company plans to use recent funds to accelerate clinical validation and regulatory submissions to enable commercialization. Financially, the company secured €2.3M in grant funding and has a €10M follow-on investment offer from the European Innovation Council.

Led · Equity · Jan 2024

Founded in 2019 and led by CEO Sandy Mou, Corxel Pharmaceuticals (formerly JiXing Pharmaceuticals) focuses on discovering, developing, and commercializing therapies for cardiometabolic conditions. Its lead candidate, CX11, is in an ongoing U.S. Phase 2 trial for obesity and overweight patients and is scheduled for a global Phase 2 study targeting Type 2 Diabetes Mellitus, with Phase 3 preparations already underway. Beyond CX11, the company’s pipeline spans assets for hypertension, acute ischemic stroke, and ophthalmologic indications such as dry eye and presbyopia. Proceeds from its recent financing will also support advancement of these additional programs and expand global operational capabilities needed for multiregional clinical trials. The company operates from offices in Berkeley Heights, New Jersey, and China. As a clinical-stage firm, Corxel has not disclosed commercial revenues, but the latest capital infusion provides significant runway to progress multiple candidates through late-stage development.

Led · Series C · Aug 2020

One Drop provides a data-powered, personalized self-care platform that delivers predictive and preventive interventions for people managing diabetes, prediabetes, high blood pressure, and high cholesterol. The platform draws on more than 13 billion health data points from users and has been downloaded over three million times. One Drop's modular architecture and user-centric experience enable expansion across multiple therapeutic areas and support whole-person care rather than single-condition management. Since 2016 its digital health solution has been available to consumers, employers, insurers, and healthcare providers, and over 20 peer-reviewed studies demonstrate significant improvements in glycemic control in as little as one month. Financially, One Drop closed a $34.7 million Series C and secured $64 million in development fees and potential commercial milestone payments from Bayer. The Bayer collaboration is intended to jointly develop digital products into Bayer's focus areas, including cardiology, oncology, and women's health, supporting the company's plans to broaden its platform's therapeutic reach. Informed Data Systems offers One Drop, a diabetes management platform combining software, hardware and services that lets users log glucose, food, insulin and physical activity. The platform supports people with Type 1, Type 2, pre-diabetes and diabetes caregivers and enables anonymous sharing and community insights. One Drop delivers actionable, data-driven insights to users on the platform and is available for iOS and Apple Watch. Led by CEO and founder Jeff Dachis, the company plans to use new funding to continue platform development and accelerate adoption among users, self-insured employers and insurers. The company is based in New York City and Austin, Texas and recently completed a Series A financing.

Led · Series C · Aug 2020

One Drop offers a data‑driven digital health platform that provides eight‑hour glucose forecasts, real‑time advice, one‑on‑one coaching and personalized health plans for people with diabetes and related conditions. The platform leverages clinical science, behavioral science and advanced AI and is fueled by more than 13 billion health data points and over three million downloads. One Drop supports management of diabetes, prediabetes, high blood pressure and high cholesterol, and delivers interventions in a user‑centric app experience. Its products and services are available via iOS and Android apps and retail partners including Walmart, Amazon, Best Buy, the Apple Store and CVS. The company recently entered a strategic agreement with Bayer to jointly develop digital health products across multiple therapeutic areas. Bayer’s commitments are intended to expand One Drop’s solution into Bayer focus areas such as cardiology, oncology and women’s health. One Drop is a mobile diabetes-management app created by Jeff Dachis that lets users log insulin levels, medication effectiveness, meals, and activities. The app launched in the App Store in April and recorded 60,000 user sessions in its first five weeks with an 89% conversion rate from download to active users. It is ranked 289th among health and fitness apps in the App Store. One Drop plans to move beyond software into hardware with a connected glucose meter due this year that will sync with the app, and it is building an Android app. The company intends to add new features and pursue partnerships with insurers and self-insured employers as it grows its user network. Financially, One Drop previously raised $1 million in angel funding and recently closed an $8 million Series A, giving it $9 million in total capital to fund product and hardware development. One Drop is an iOS app that lets people with type 1 and type 2 diabetes log glucose readings, insulin medication, meals (via photos) and physical activity. The app aggregates those inputs into a running log to show how different factors affect blood sugar and to inform treatment discussions with doctors. It also includes a social “We” section where users can view peers’ profiles and provide encouragement by liking entries. One Drop launched in the App Store and is free on iOS today. Founder Jeff Dachis, who was diagnosed with Type-1 diabetes at 47, built the product to cover four core components he found lacking in existing tools. Dachis plans to add a monthly subscription later in the year that would include test strips and a Bluetooth-enabled glucose monitor device.